200,000+ products from a single source!

sales@angenechem.com

Home > IDT production

IDT production

IDT production in various fungi

To date, more than 50 fungal species have been demonstrated to produce paspaline-derived IDTs (Supplementary Table S1). The great majority of IDT producer fungi belong to only two ascomycetous classes in the Pezizomycotina subphylum: the Eurotiomycetes (Aspergillus, Penicillium, Emericella and Eupenicillium species in the Aspergillaceae and Trichocomaceae families within the Eurotiales order) and the Sordariomycetes (Claviceps, Epichloë, Escovopsis, Neotyphodium, Periglandula and Tolypocladium species in the Clav ic ipi t a cea e , Hypoc r eace ae and Ophiocordycipitaceae families in the Hypocreales order).
In the order Eurotiales (class Eurotiomycetes), at least 24 Penicillium and Eupenicillium species have been shown to produce various paspaline-derived IDTs (Supplementary Table S1). The most common IDT in these fungi is penitrem A, a metabolite that is of paramount importance for the con- tamination of foodstuffs with mycotoxins. One of the most important model organisms used in IDT biosynthetic studies is the saprophytic species P. paxilli, which produces paxilline. A set of bioactive paxilline analogues were also isolated from Penicillium camemberti, a white mold that is widely used in cheese ripening.
Among the more than 10 Aspergillus and Emericella spe- cies that produce paspaline-derived IDTs, the notorious afla- toxin producer A. flavus is also capable of synthetizing aflatrem A and at least two additional aflatrem congeners. Aflatrem and paspaline were also detected in cultures of two other Aspergillus species, A. minisclerotigenes and
A. parvisclerotigenus. Importantly, the koji mold Aspergillus oryzae was shown to produce 13-desoxypaxilline, a common intermediate for aflatrem biosynthesis. Some other Aspergilli, including A. desertorum, A. foveolatus, and A. striatus are verified paxilline producers while A. alliaceus synthesizes two paxilline-like IDTs in axenic cultures.
In the order Hypocreales (class Sordariomycetes), at least 13 species produce paspaline-derived IDTs (Supplementary Table S1). In the family Clavicipitaceae, C. paspali and
C. cynodontis yield paspalitrems while the well-known ergot alkaloid producer C. purpurea synthesizes only less complex IDTs such as paspaline. Epichloë gansuensis produces paxilline, while the IDT spectra of two additional clavicipitaceous fungi, N. lolii and E. festucae are rather dif- ferent. These two fungi form IDTs with the C11(12) epoxide, giving rise to terpendoles and the more elaborate lolitrems. Meanwhile, Periglandula ipomoeae strains, symbionts of morning glory, also produce terpendole analogues such as terpendoles C, K, and E (Schardl et al. 2013; Lee et al. 2017; Gardner et al. 2018). Fungi in two other hypocrealean families also produce paspaline-derived IDTs. Thus, T. album (basionym Chaunopycnis alba; family Ophiocordycipitaceae) is another important terpendole producer, while Escovopsis weberi (family Hypocreaceae) produces shearinines.
Interestingly, the zygomycetous fungus Mucor irregularis has recently been shown to yield penitrems and the related rhizovarins. M. irregularis (family Mucoraceae, order Mucorales, phylum Mucoromycota) is the only currently known fungus outside the Ascomycota phylum that produces paspaline-derived IDTs (Gao et al. 2016).

Gene clusters for IDT biosynthesis

To date, ten gene clusters for the biosynthesis of the paspaline- derived IDTs have been identified (Fig. 3), including those for penitrems (P. crustosum and P. simplicissimum) (Liu et al. 2015; Nicholson et al. 2015), paxilline (P.  paxilli) (Scott  et al. 2013), shearinines (P. janthinellum) (Nicholson et al. 2015), aflatrems (A. flavus and A. oryzae) (Zhang et al. 2004; Nicholson et al. 2009), paspalitrems (C. paspali) (Kozák et al. 2018), terpendoles (T. album) (Motoyama et al. 2012), and lolitrems (N. lolli and its anamorph E. festucae) (Young et al. 2006; Saikia et al. 2012). All these gene clusters contain orthologues of the paxG, paxM, paxC and paxB genes whose enzyme products are collectively responsible for the biosynthesis of paspaline as described in section 3.1 (Fig. 1, Supplementary Table S2). The only exception is the terpendole K gene cluster of T. album that is missing a GGPP synthase gene dedicated to IDT biosynthesis, indicat- ing that this precursor is supplied by the primary metabolic GGPP synthase of the strain (Motoyama et al. 2012).
In addition to the paxGMCB orthologues, all biosynthetic gene clusters for the paspaline-derived IDTs elucidated so far also contain genes similar to paxP and paxQ (Supplementary Table S2). The encoded cytochrome P450 monooxygenases are responsible for the oxidations that channel paspaline to- wards the paxilline, paspalinine or terpendole E-type cores of the various paspaline-derived IDT families (Fig. 2). All bio- synthetic gene clusters for paspaline-derived IDTs also feature additional genes encoding enzymes for the subsequent modi- fication of the angled hexacyclic skeleton (Fig. 3, Supplementary Table S2).
The known biosynthetic gene clusters for the different paspaline-derived IDT families show little synteny. The only exception to date is the pair of clusters for paxilline and the shearinines (Fig. 3), where the order and orientation of the genes are the same, except for the absence of a janJ orthologue in the paxilline gene cluster (Liu et al. 2016). In contrast, clusters that are derived from closely related species that produce metabolites belonging to the same IDT family are highly syntenic. For example, A. flavus and A. oryzae RIB40 contain aflatrem-type gene clusters with identical organiza- tions and chromosomal locations, with the corresponding Atm enzymes of the two species showing at least 95% pairwise identities. Nevertheless, A. oryzae produces non- prenylated paspalenes due to a single nucleotide insertion into exon 7 that renders atmQ nonfunctional (Nicholson et al. 2009; Qiao et al. 2010; Rank et al. 2012).
Unusually for fungal secondary metabolite biosynthetic gene clusters, several of the IDT clusters seem to be distribut- ed into multiple loci, although sequence closure of draft ge- nomes may lead to the revision of this notion in some cases. Thus, the penitrem biosynthetic genes of P. simplicissimum, but not those of P. crustosum, are separated into two subclus- ters. The ptm2 and ptm1 subclusters of P. simplicissimum are syntenic with genes PC-23 - penO and penG - PC-05, respec- tively, within the penitrem cluster of P. crustosum. The aflatrem biosynthetic gene  clusters of A. flavus  and
A. oryzae RIB40 are divided into two loci that reside on dif- ferent chromosomes (the atm1 subcluster is located on chro- mosome 5, while atm2 is on chromosome 7) (Nicholson et al. 2009). The paspalitrem gene cluster also spans two separate contigs on the genome sequence assembly of C. paspali RRC- 4128 (Schardl et al. 2013). These two contigs contain all the genes necessary for the biosynthesis of paspalitrems, except for the one that catalyzes C32 hydroxylation of paspalitrem A to yield the end product paspalitrem B (Kozák et al. 2018). Finally, the 11 known genes for lolitrem biosynthesis are dis- persed into three ltm subclusters in N. lolli and E. festucae. Subcluster 1 is separated from subcluster 2 by a 35-kb geno- mic  region, while subcluster 3 is located at 16 kb from subcluster 2. The interspersed genomic regions are rich in AT repeats and retrotransposon elements, indicating that the com- posite ltm1-3 cluster resides in a rapidly evolving region of the genome, such as a chromosomal sub-telomeric region. This capacity for rapid evolution is underlined by the observation that the ltm1-3 composite cluster may have been duplicated in its entirety in N. lolii strain Lp19, while subcluster 3 could not be detected in the very closely related strain Lp1. In contrast,
E. festuceae F11 contains a single copy of the ltm1-3 compos- ite cluster (Young et al. 2006).

Regulation of IDT production

The regulation of IDT production has received surprisingly little attention up till now. Thus, no cluster-specific regulator has been validated in any IDT gene cluster so far. Although the penitrem gene clusters of P. simplicissimum and P. crustosum feature putative regulatory genes (ptmS and PC-06), the func- tion of these genes has not been determined experimentally (Liu et al. 2015). Similarly, the integration of IDT biosynthesis with other metabolic and morphogenetic processes also re- mains opaque. In A flavus, abundant aflatrem production is associated with sclerotia formation (Ehrlich and Mack 2014) while reduced aflatrem production results from the deletion of the ndsC gene encoding a global regulator of secondary metab- olism and asexual development (Gilbert et al. 2016).
While N. lolii and E. festucae produce lolitrems in planta only (Young et al. 2006), other IDT producers also biosynthesize these compounds in axenic cultures (Motoyama et al. 2012; Nicholson et al. 2015; Kozák et al. 2018). A. oryzae produces the paxilline precursor 13-desoxypaxilline under specific growth conditions only (Rank et al. 2012; Fountain et al. 2016). In contrast,
T. album produces large amounts of terpendoles in various me- dia, suggesting that this biosynthetic pathway is not subject to a strict regulation in this strain (Motoyama et al. 2012). Similarly,
P. crustosum strains isolated from different environments and substrates consistently produce penitrems (Frisvad and Filtenborg 1983; Yamaguchi et al. 1993; Sonjak et al. 2005). However, a variety of abiotic factors were still found to influence the production of these IDTs (Kalinina et al. 2017). Thus, culti- vation in the dark at relatively low temperatures (22 °C); glucose or rhamnose as the carbon source; and supplementation of the medium with glutamate all increase penitrem production by
P. crustosum. Interestingly, supplementation with tryptophan has the opposite effect in this fungus (Kalinina et al. 2017), in agreement with the notion that indole-3-glycerol phosphate and not tryptophan is the real precursor for IDT biosynthesis (Liu  et al. 2015). In contrast, tryptophan serves as both a precursor and an inducer for ergot alkaloid biosynthesis in C. purpurea (Řeháček et al. 1971). In P. nigricans, penitrem production and sporulation are both induced by calcium chloride (Mantle et al. 1984), while CuSO4 increases penitrem production by
P. crustosum (Kalinina et al. 2017). 


Oxidative stress can also be an important factor for the regulation of tremorgenic IDT biosynthesis. Aflatrem biosyn- thesis is generally upregulated in A. flavus by hydrogen per- oxide, although different isolates react differently to varied concentrations of H2O2 (Fountain et al. 2016). In contrast, H2O2 has a strong inhibitory effect on penitrem biosynthesis by P. crustosum.


IDTs as threats to agriculture, public health, and the fermentation industries
Agricultural threats

Among the known IDTs, lolitrems and paspalitrems represent the most severe danger for livestock. These compounds cause a tremorgenic syndrome in grazing animals, referred to as Bryegrass stagger^ in the case of lolitrem B ingestion  (Fletcher
and Harvey 1981; Gallagher et al. 1981), and BPaspalum
stagger^ or BBermuda grass stagger^ in the case of paspalitrem mycotoxicoses  (Cole et al. 1977; Uhlig et al.  2009).  Ryegrass
stagger is typically caused by grazing on Lolium perenne (peren- nial ryegrass) infected by N. lolii (Gallagher et al. 1981), since lolitrem B is abundant in the N. lolii - L. perenne association (Philippe 2016). Ryegrass stagger is most frequently reported in New Zealand and Australia, and the affected animals include sheep, cattle and horses (di Menna et al. 2012). To manage rye- grass stagger, different endophyte strains with altered mycotoxin production spectra were isolated and tested. Among these, the endophytic fungus AR37 does not produce lolitrem B, but biosynthesizes epoxy-janthitrem in high concentrations. While epoxy-janthitrem is just as toxic to insects as lolitrem B, it does not cause a tremorgenic syndrome on grazing animals (Thom et al. 2013).
Outbreaks of Paspalum stagger are frequent in South Africa but case reports from the Americas, Europe, and New Zealand were also published (Mantle et al. 1978; Moyano et al. 2010; Cawdell-Smith et al. 2010). C. paspali infecting Paspalum dilatatum (Dallis grass) and C. cynodontis infecting Cynodon dactylon (Bermuda grass) produce similar paspalitrem IDT pro- files (Uhlig et al. 2009). Ingestion of sclerotia containing these toxins causes a tremorgenic syndrome with very similar symp- toms to that of ryegrass stagger (Moyano et al. 2010). Just as with lolitrem B intoxication, the affected animals usually recover rap- idly after being removed from the infected pasture (Moyano et al. 2010; Cawdell-Smith et al. 2010).
Grazing on morning glories, most frequently on Ipomoea asarifolia and Ipomoea muelleri, may also cause a tremorgenic syndrome on livestock (Gardiner et al. 1965; Medeiros et al. 2003; Dorling et al. 2004; Carvalho de Lucena et al. 2014). This toxicosis is also associated with the presence of IDTs (Lee et al. 2017), produced by seed- transmitted endophytic fungi, most likely P. ipomoeae (Schardl et al. 2013; Lee et al. 2017). The main IDT congeners isolated from endophyte-infected I. asarifolia and I. muelleri are terpendole K, 11-hydroxy-12,13-epoxyterpendole K and 6,7-dehydroterpendole A (Lee et al. 2017).
A ryegrass stagger-like syndrome, Bhuecu’s disease^ has been observed on sheep, horses, cattle, and goats in Argentina.
This is caused by the ingestion of the grass Poa huecu con- taminated with penitrem A and B, produced by Penicillium species (Scuteri et al. 1992). Penitrem A may also contaminate the soil, and ingestion of such soil by grazing animals can also cause a tremorgenic syndrome (Patterson et al. 1979). However, most case reports of penitrem A intoxications in- volve the ingestion of moldy food by pets, most frequently dogs (Hayes et al. 1976; Richard et al. 1981; Hocking et al. 1988; Walter 2002). Symptoms on dogs include generalized convulsion, ataxia, vomiting, tremors, frequent urination and defecation, mydriasis (dilation of the pupil), polypnea (panting), and hyperthermia (Richard and Arp 1979; Richard et al. 1981). Typically, the affected animals recover within a few weeks or months, but ataxia may still remain observable even years later in severe cases of intoxication (Eriksen et al. 2010).
Contamination of animal feedstuffs by spoilage fungi that produce mycotoxins including IDTs such as penitrem A (Stoev et al. 2010) represents another worldwide threat to the livestock industry. Such problems are independent of the geographical location or the origin of the feed from industrial or family-owned farms (EFSA Panel on Contaminants in the Food Chain (CONTAM) 2012).

Public health threats

Among IDTs, the toxic effects of only penitrem A and its analogues have been studied in depth, mainly in mice (Eriksen et al. 2013). Valuable information on the adverse physiological effects of these compounds on mammals also came from case reports on poisoned dogs that consumed var- ious moldy foods infected by P. crustosum (Eriksen et al. 2010; Eriksen et al. 2013). Tremorgenic mycotoxicoses likely caused by penitrem A and/or other mycotoxins produced
P. crustosum have only been reported very rarely in humans (Eriksen et al. 2013), and were connected to either the con- sumption of mold-contaminated food (Lewis et al. 2005) or drink (Cole et al. 1983), or resulted from exposure to moldy silage (Gordon 1993). It is important to note that food wastes from private households may contain high concentrations of tremorgenic mycotoxins, e.g., as high as 35–7500 μg/kg of penitrem A (Rundberget et al. 2004).
The neurotoxic effects of penitrem A include tremors, con- vulsions, ataxia and nystagmus (involuntary eye movement) (Eriksen et al. 2013). In humans, symptoms affecting the gas- trointestinal tract, such as nausea, vomiting, and bloody diar- rhea have also been recorded (Cole et al. 1983). The toxicokinetic characteristics of this lipophilic molecule are relatively well-known and include (i) rapid absorption through biological membranes, (ii) rapid distribution within the body through the blood vessels to the liver, the kidneys and the central nervous system (penitrem A can penetrate the blood- brain barrier), (iii) metabolism in the liver to yield more hy- drophilic compounds, and (iv) excretion through the bile into the feces (Moldes-Anaya et al. 2009; Eriksen et al. 2010; Moldes-Anaya et al. 2012; Eriksen et al. 2013).
Penitrem A interferes with GABAergic neurotransmission in the central nervous system by inhibiting the GABA(A) re- ceptors in the forebrain and in the cerebellum in a region- specific manner (Moldes-Anaya et al. 2011; Eriksen et al. 2013). In addition, this IDT is a potent antagonist of the high-conductance Ca2+-activated potassium channels (BK channels) in smooth muscles and peripheral tissues (Knaus et al. 1994; Eriksen et al. 2013). Importantly, lolitrem B and paxilline produced by N. lolii and E. festuce also inhibit these potassium channels, leading to ryegrass staggers in livestock (Dalziel et al. 2005; Imlach et al. 2008). Penitrem A-induced neurotoxicity may also be linked to the oxidative stress- inducing effect of this compound, as shown in cerebellar gran- ule neurons in rats (Berntsen et al. 2017).
Additional harmful physiological effects of IDTs may in- clude genotoxicity, as observed for paxillin in human lympho- cytes (Sabater-Vilar et al. 2003). It is noteworthy that both
P. crustosum extracts and penitrem A showed considerable cytotoxicity in vitro against human lung cancer, human hepa- toma carcinoma, murine fibroblast and murine neuroblastoma cell lines (Bunger 2004). The physiological effects of IDTs might be even more varied and severe because toxigenic fungi typically produce a wide spectrum of harmful secondary me- tabolites (Bunger 2004; Andersen and Frisvad 2004; Santini et al. 2014; Prencipe et al. 2018). Unfortunately, the synergis- tic behavior of these compounds is a notoriously understudied area of mycotoxicology.
Paspalitrem IDTs are relatively rarely implicated in out- breaks of toxic syndromes in humans. One such case involved an outbreak of tremors in India in 1946. At that time, Paspalum scrobiculatum, a type of millet, was consumed in certain parts of India because of a shortage of rice. Tellingly, the paspalitrem producer C. paspali was isolated from the unwholesome grain (Aaronson 1988). Even today, another IDT producer, C. purpurea is often isolated from rye and barley, and paxilline can be detected in such specimen at the maximum concentration of 0.6 mg/kg (Bauer et al. 2017).
C. purpurea sclerotia contain at least seven paspalenes, in- cluding paspaline (Uhlig et al. 2014). This raises the interest- ing possibility that these toxins may have played a role in the development of the feared symptoms of ergotism in the Middle Ages. Some authors, including Bauer and coworkers hypothesized that IDTs might have contributed to outbreaks of convulsive ergotism during history (Bauer et al. 2017).


Although the daily exposure of consumers to various IDTs is unknown, these toxic compounds have been detected in a number of food and drink products in highly variable concen- trations, depending on the geographical location. Penitrem A and its producer, the food spoilage fungus P. crustosum have been detected in several agricultural products and foodstuff, such as beer, cheese, chestnut, meat products, vegetables, pud- ding, grape berries, honey, and sausage (El-Banna and Leistner 1988; Overy et al. 2003; Sengun et al. 2008; Tancinova and Labuda 2009; Kacaniova et al. 2012; Santini et al. 2014; Camardo Leggieri et al. 2016; Olsen et al. 2017; Prencipe et al. 2018). Of course, penitrem A is not the only IDT that can be detected in contaminated foods. Paxilline and other IDTs were found in moldy tomatoes infected with Penicillium tularense (Andersen and Frisvad 2004). Lolitrem B and epoxy- janthitrem were observed in the fat and milk of growing and lactating animals that grazed on contaminated tall fescue (Miyazaki et al. 2004; Finch et al. 2012; Finch et al. 2013; Shimada et al. 2013; Zbib et al. 2015). The maximum concen- tration of these IDTs in cow milk reached 5 ng/ml and 109 ng/ml for lolitrem B and epoxy-janthitrem, respectively (Finch et al. 2013). Miyazaki et al. (2004) measured 210 ppb lolitrem B in the perirenal fat of Japanese Black cattle feeding on contaminated ryegrass (Miyazaki et al. 2004). However, the concentrations of these IDTs decrease rapidly in vivo when the animals are removed from the contaminated pasture, thus re- ducing the prevalence of food containing these two mycotoxins and limiting the threat to human health (Miyazaki et al. 2004; Finch et al. 2013).
Today, highly sensitive HPLC-MS methods are available to facilitate the detection of mycotoxin contaminants in food and drink samples (Rundberget and Wilkins 2002). A recent sur- vey (Kalinina et al. 2018) revealed that 10% of cheese samples taken from the European single market contained penitrem A at an average concentration of 28.4 μg/kg and with a maxi- mum concentration of 429 μg/kg. Considering such observa- tions, it would be important to devise standardized analytical protocols for tremorgenic IDT mycotoxins. Even more impor- tantly, it would be highly desirable for national and interna- tional regulatory agencies to define the maximum legally per- mitted levels of tremorgenic IDTs in human food and animal feed, similar to legal limits established for other mycotoxins such as aflatoxin (Medeiros et al. 2012; Oliveira et al. 2014).


Threats for the fermentations industries

C. paspali is used to produce ergot alkaloids in the pharma- ceutical industries for the manufacture of drugs against mi- graine and for the treatment of Parkinson’s disease. IDT bio- synthesis by C. paspali during industrial fermentations or ag- ricultural production on infected grasses represents both an economic and a safety problem for the manufacturers. Precursors and cofactors that may be utilized for ergot production are depleted by IDT biosynthesis, reducing pro- ductivity. At the same time, IDTs are hazardous impurities that must be removed from ergot alkaloid products and must also be safely disposed (Kozák et al. 2018).
A. oryzae is widely used in biotechnology and the food industry.  This fungus is  the domesticated descendant   of
A. flavus. While the genotypes of A. oryzae and A. flavus are nearly identical, these fungi can still be distinguished by their morphological and physiological characteristics, and by their secondary  metabolite  profiles  (Frisvad et al. 2018). While
A. oryzae does not produce aflatoxin (Barbesgaard et al. 1992; Tao and Chung 2014), certain isolates of A. oryzae were demonstrated to produce tremorgenic paspaline-type IDTs such as 13-desoxypaxilline (Qiao et al. 2010; Rank et al. 2012). Production of these IDTs may represent an overlooked risk factor for fermented food products.
A possible solution may be to eliminate the production of IDT mycotoxins during various fermentations, for example by inactivating key IDT biosynthetic genes. This was demonstrat- ed by the knockout of the idtCBGF paspalitrem biosynthetic genes in the industrially important ergot producer C. paspali. This led to the complete abrogation of IDT biosynthesis during fermentations, while the production of ergot alkaloids remained undisturbed with this strain (Kozák et al. 2018).


Future perspectives
Potential medical applications

Paspaline-derived IDTs are not in current medical use. Nevertheless, these metabolites show potent and wide- ranging bioactivities and have been considered for pharmaceu- tical development over the years. It is noteworthy that terpendole congeners were isolated in a systematic screening for acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors of microbial origin (Huang et al. 1995). ACAT inhibitors are po- tential agents for the prevention of atherosclerosis (Lee et al. 1998). The most potent inhibitor is terpendole C (IC50: 2.1 μM) but terpendole D (IC50: 3.2 μM) was considered even more promising since that congener displayed relatively low cytotox- icity against J774 macrophages (Huang et al. 1995). After the discovery of two ACAT isozymes in mammals (Anderson et al. 1998; Cases et al. 1998), isozyme selectivity became a prereq- uisite for potential anti-atherosclerotic agents (Giovannoni et al. 2003). Testing the selectivity of a number of microbial ACAT inhibitors revealed that terpendole C inhibits both ACAT iso- zymes, reducing the enthusiasm for the further clinical devel- opment of these IDTs (Ohshiro et al. 2007).
Terpendoles were re-discovered in a systematic screening for specific M phase cell cycle inhibitors where terpendole E was found to specifically inhibit the human kinesin Eg5 (Nakazawa et al. 2003), a potential target for cancer therapy (Knight and Parrish 2008; Sarli and Giannis 2008). Terpendole E does not affect microtubules directly, but in- duces the formation of monopolar mitotic spindles in the M phase, similar to monastrol (Nakazawa et al. 2003; Tarui et al. 2014; Sheff et al. 2017). To increase the production of terpendole E that is an intermediate of terpendole K biosyn- thesis and is thus produced only in low amounts, the terP gene was inactivated in T. album leading to the accumulation of terpendole E (Motoyama et al. 2012). The same terP knockout strain also produces the novel shunt product 11-ketopaspaline (Tarui et al. 2014). Later studies revealed that terpendole E and 11-ketopaspaline are both potent inhibitors of the microtubule-stimulated ATPase activity of Eg5. Importantly, these terpendoles not only inhibit the wild type Eg5, but retain excellent activity against Eg5 variants that are resistant to the known Eg5 inhibitors S-trityl-L-cysteine and GSK-1 (Tarui et al. 2014).
Penitrems show in vitro antiproliferative, anti-haptotactic (cell migration inhibitory) and anti-invasive activities against human breast cancer cell lines. Penitrem A induces G1 cell cycle arrest and upregulates the arrest protein p27 (Goda et al. 2018). The documented synergistic effects of penitrem A treat- ment with anti-HER drugs may have a significant impact on future development of breast cancer chemotherapies (Goda et al. 2018). Interestingly, the early biosynthetic intermediates paspaline and emindole SB also show noticeable antiprolifera- tive and antimigratory activities, with the anti-haptotactic activ- ity of paspaline almost equipotent to that of the more elaborate congener penitrem A (Sallam et al. 2013a; Sallam et al. 2013b). These notable activities of penitrem A are due, at least in part, to the inhibition of the Wnt/β-catenin pathway (Sallam et al. 2013a) that is a validated target of novel anticancer drugs (Lu et al. 2011). However, the BK channel (high-conductance Ca2+-activated potassium channel) inhibitory and tremorgenic activities of these IDTs present a formidable obstacle towards the development of penitrems as novel drugs (Sings and Singh 2003). Inhibition of the α-subunit of the BK channel interferes with neurotransmitter release mechanisms and neuroreceptors in the central and the peripheric nervous systems. To overcome these challenges, new penitrem analogues were synthesized. Some of these lack the BK channel inhibitory and tremorgenic activities while still repress β-catenin in human breast cancer cells (Sallam et al. 2013a). Another interesting approach is to mitigate the undesired effects of penitrems in a combination therapy with preventative agents such as astaxanthin or docosahexaenoic acid. Simultaneous application of penitrem A with these agents in rats significantly reduced toxicity and reversed the BK channel blockade associated with penitrem A alone (Goda et al. 2016).
While paspaline-derived IDTs are associated with tremorgenic activities, emindole SB-derived IDTs such as nodulisporic acids display highly potent insecticidal activities without observable adverse effects in mammals (Shoop et al. 2001). Thus, non-tremorgenic IDT analogues may find appli- cations as pesticides in agriculture or even as anti-parasitic agents against insects feeding on humans.
Conversely, the potent BK channel inhibitory activity of penitrems may also be utilized in the future. The standard inhib- itor for BK channels is iberiotoxin whose high price and mem- brane impermeability makes its use less than ideal for studies in organ models or whole animals. The higher membrane perme- ability, potency and efficacy of penitrem A may recommend this IDT as a good alternative to iberiotoxin for studying BK chan- nels in vitro and in vivo (Stewart et al. 2012; Asano et al. 2012; Kyle et al. 2013; Needham et al. 2014).
Invasive fungal infections are an important medical prob- lem, particularly in immunocompromised patients. However, treatment of invasive candidiasis is restricted to only a few drug families with a limited number of mechanisms of action (Tkacz and DiDomenico 2001). The toxicity of amphotericin B, and the emergence of resistance in the clinically relevant Candida albicans species against the azoles and the candins presents a clear demand for the development of new therapeu- tic strategies (Kathiravan et al. 2012). Importantly, shearinines D and E block the formation of biofilms by C. albicans (You et al. 2013). Biofilm formation makes the treatment of fungal infections very problematic, because biofilms constitute a bar- rier that can prevent antifungal drugs from reaching the fungal cells (Douglas 2003; Nett et al. 2010; Nett et al. 2011).
C. albicans treated with shearinine D forms an irregular, sparse layer instead of a well-developed biofilm. Co- application of shearinine D or E synergistically enhanced the potency of amphotericin B against clinical Candida isolates (You et al. 2013).
Systematic screening for natural compounds active against the influenza A virus subtype H1N1 led to the isolation and charac- terization of an array of IDT congeners from P. camemberti. Three novel and six known paspaline- and paxilline-derived IDT analogues showed significant antiviral activity (IC50 17.7–
73.3 μM) (Fan et al. 2013), raising hopes that novel antiviral agents may be developed from these IDTs in the future.

Industrial scale production of IDTs using filamentous fungi

The industrial-scale production of paspaline-derived IDTs for future medical and agricultural applications requires careful consideration of the potential producer strains. For example,
P. paxilli has been extensively used to clarify the individual steps of IDT production (Young et al. 2001). However, the pharmaceutical industry has yet to invest in the strain devel- opment and fermentation process optimization of this strain. Similarly, N. lolii may be difficult to adopt for the large-scale production of secondary metabolites due to its fastidious growth habits, genetic instability, and its requirement for a plant host for IDT production (Wiewióra et al. 2015).


Only a few studies investigated the production of IDTs in laboratory scale fermentations. Thus, P. nigricans produced 60 mg/L penitrem in a 60-L stirred fermentor in 5 days (Mantle et al. 1984). Engineered T. album accumulated 36 mg/L terpendole E, an intermediate of terpendole K bio- synthesis, in a 30 L fermentor in 2 days (Motoyama et al. 2012). Kalinina and coworkers demonstrated that the spec- trum of penitrems produced by P. crustosum can also be con- trolled by varying the chemical and physical conditions of the fermentation (Kalinina et al. 2017). Encouragingly, C. paspali is currently used for ergot alkaloid production in the pharma- ceutical industry. Although these fermentations have not been optimized for IDT production, the significant knowledge base available for the safe and economical industrial scale fermen- tation and the genetic manipulation of this fungus (Arcamone et al. 1960; Tudzynski et al. 2001; Kozák et al. 2018) may recommend C. paspali as a useful candidate to produce IDT congeners in the future.

Heterologous biosynthesis of IDTs

Domesticated microbial hosts for the heterologous expression of biosynthetic pathways are becoming increasingly important for the characterization of biosynthetic pathways and the clar- ification of reaction mechanisms. As a prominent example, the Oikawa group has been developing a heterologous production system for secondary metabolites. In this system, biosynthetic genes are cloned into multiple expression vectors and co- integrated into the genome of the domesticated filamentous fungus A. oryzae. In an influential set of publications, Oikawa and coworkers have used this expression system for the reconstitution of the biosynthesis of various IDTs to clarify the individual biosynthetic steps (Oikawa et al. 2016). Thus, the biosynthesis of paspaline was reconstituted in 2012 using
A. oryzae transformants producing the P. paxilli IDT biosyn- thetic enzymes PaxG, PaxC, PaxM and PaxB (Liu et al. 2015). Adding the paxP and paxQ genes yielded paxilline in
A. oryzae. In 2014, seven genes from the aflatrem biosynthetic locus of A. flavus were expressed in the A. oryzae host, leading to the heterologous production of aflatrem A and β-aflatrem in addition to paspaline and paspalinine (Tagami et al. 2014). In 2015, the same A. oryzae chassis was utilized to dissect the biosynthesis of penitrems by functionally analyzing 13 of the 17  genes encoded in  the  biosynthetic gene cluster  of
P. simplicissimum (Liu et al. 2015). The same A. oryzae het- erologous expression system was also used to clarify the bio- synthesis of shearinines from P. janthinellum (Liu et al. 2016). Other hosts have also been used to express IDT biosynthet-
ic gene clusters. For example, a versatile multigene expression system termed MIDAS was developed to express biosynthetic gene clusters in a P. paxilli strain with the entire paxilline biosynthetic cluster deleted (van Dolleweerd et al. 2018). This system was used to express key biosynthetic genes from Hypoxylon pulicicidum to produce nodulisporic acid interme- diates and congeners (Van de Bittner et al. 2018). Although nodulisporic acid is not a paspaline-derived IDT and is thus not the subject of this review, the work still shows that strains derived from IDT producers can be useful hosts to produce other bioactive molecules. Meanwhile, nodulisporic acid de- rivatives are potent insecticides that lack observable adverse effects in mammals, including the tremorgenic activities asso- ciated with the paspaline-derived IDT core.
Combinatorial biosynthesis of novel, unnatural IDTs in synthetic biological platforms is another promising applica- tion. To design such a platform, the Tang group has used Saccharomyces cerevisiae as the chassis for the heterologous production of epoxy-geranylgeranyl indole (Tang et al. 2015). Co-expression of various IDT cyclases, some with previously unknown product specificities yielded not only paspaline (1.5 mg/L), but also various seco-IDTs and aflavinine- or anominine-type Markovnikov-derived cyclic scaffolds. This work demonstrates that diversity-oriented combinatorial bio- synthesis with enzymes coopted from distinct and even or- thogonal IDT biosynthetic pathways may be used to generate diverse, drug-like chemical matter towards the discovery of future medications. Presumably, such synthetic biological platforms will also be useful in the future for the large-scale and economical production of IDT congeners for medical or agricultural applications.

Funding information This work was supported by the European Union and the European Social Fund through the project EFOP-3.6.1-16-2016- 00022 (to I. P.), the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary (Biotechnology thematic program to I. P. and I. M.) and the U.S. National Institutes of Health (NIGMS 5R01GM114418 to I. M.).

Compliance with ethical standards

Conflict of interest I. P. declares no conflict of interests. I. M. has disclosed financial interests in Teva Pharmaceuticals Works Ltd., Hungary, and DSM Nutritional Products, LLC, USA, which are unrelated to the subject of the research presented here. L. K., Z. S., and L. T. are employees of Teva Pharmaceutical Works Ltd., Hungary. Responsibility for the conclusions drawn, and the opinions expressed in this article are solely those of the authors and are not shared by Teva Pharmaceutical Works Ltd.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the Authors.

Publisher’s Note Springer Nature remains neutral with regard to jurisdic- tional claims in published maps and institutional affiliations.

Over 100,000 products now available from Angene:

CAS No. 113509-20-9

1,3-Dithiolane, 2-(3,5-dimethylphenyl)-

Catalog No.:AG0008UO MDL No.:

MF:C11H14S2 MW:210.3589

CAS No. 113509-22-1

1,3-Dithiolane, 2-(2-bromophenyl)-

Catalog No.:AG0008UN MDL No.:

MF:C9H9BrS2 MW:261.2018

CAS No. 113509-39-0

Palladium, tris[(2-ethenylphenyl)diphenylphosphine]-

Catalog No.:AG0008UM MDL No.:

MF:C60H51P3Pd MW:971.3882

CAS No. 113509-50-5

2H-Pyran-3(6H)-one, 2-(1,1-dimethylethyl)-6-hydroxy-

Catalog No.:AG0008UL MDL No.:

MF:C9H14O3 MW:170.2057

CAS No. 113509-54-9

Adenosine, N-methyl-, 1-oxide

Catalog No.:AG0008UK MDL No.:

MF:C11H15N5O5 MW:297.2673

CAS No. 113509-58-3

2-Pyridinamine, N-methyl-5-nitro-, 1-oxide

Catalog No.:AG0008UJ MDL No.:

MF:C6H7N3O3 MW:169.1381

CAS No. 113509-61-8

Phenylalanine, N-(2-chloro-1-oxopropyl)-, (S)- (9CI)

Catalog No.:AG0008UI MDL No.:

MF:C12H14ClNO3 MW:255.6975

CAS No. 113509-67-4

Benzenemethanamine, N-(fluoromethyl)-N-methyl-

Catalog No.:AG0008UH MDL No.:

MF:C9H12FN MW:153.1967

CAS No. 1135099-32-9

Imidazo[1,2-a]pyridin-3-amine, hydrochloride (1:1)

Catalog No.:AG0008U1 MDL No.:MFCD26743577

MF:C7H8ClN3 MW:169.6115

CAS No. 113511-19-6

5H-1,4-Benzodioxepin-2,5(3H)-dione

Catalog No.:AG0008UG MDL No.:

MF:C9H6O4 MW:178.1415

CAS No. 113511-22-1

2-Thiazolamine, 5-bromo-4-phenyl-, hydrobromide (1:1)

Catalog No.:AG0008UF MDL No.:MFCD09972265

MF:C9H8Br2N2S MW:336.0462

CAS No. 113511-26-5

1,3-Benzodioxole-5-carboxylic acid, 4-bromo-7-methoxy-

Catalog No.:AG0008UE MDL No.:

MF:C9H7BrO5 MW:275.0529

CAS No. 113511-49-2

1,3-Benzodioxole-5-propanol, γ-amino-, hydrochloride (1:1)

Catalog No.:AG0008UD MDL No.:MFCD06211985

MF:C10H14ClNO3 MW:231.6761

CAS No. 113512-14-4

1H-Purine-2,6-dione, 3,7-dihydro-8-[(2-hydroxyethyl)thio]-3,7-dimethyl-

Catalog No.:AG0008UC MDL No.:

MF:C9H12N4O3S MW:256.2816

CAS No. 113512-19-9

2,4-Pyrimidinediamine, 6-ethyl-5-(4-methoxyphenyl)-

Catalog No.:AG0008UB MDL No.:

MF:C13H16N4O MW:244.2923

CAS No. 113512-25-7

3-Hexanone, 4-(acetyloxy)-6-phenyl-

Catalog No.:AG0008UA MDL No.:

MF:C14H18O3 MW:234.2909

CAS No. 113512-26-8

L-Alanine, N-chloro-, hydrochloride (9CI)

Catalog No.:AG0008U9 MDL No.:

MF:C3H7Cl2NO2 MW:159.9992

CAS No. 113512-57-5

Phenol, 2,4-difluoro-5-nitro-

Catalog No.:AG0008U8 MDL No.:MFCD08443942

MF:C6H3F2NO3 MW:175.0897

CAS No. 113512-71-3

Phenol, 5-amino-2,4-difluoro-

Catalog No.:AG0008U7 MDL No.:MFCD04973718

MF:C6H5F2NO MW:145.1068

CAS No. 113512-73-5

Pyridine, 4-[(4-methylphenyl)sulfinyl]-

Catalog No.:AG0008U6 MDL No.:

MF:C12H11NOS MW:217.2868

CAS No. 113513-27-2

1H-Pyrazole-4-carbonitrile, 3-amino-5-(3-aminopropyl)-

Catalog No.:AG0008U5 MDL No.:MFCD02370767

MF:C7H11N5 MW:165.1957

CAS No. 113513-36-3

Ethanethiol, 2-[(3-amino-1H-1,2,4-triazol-5-yl)thio]-

Catalog No.:AG0008U4 MDL No.:

MF:C4H8N4S2 MW:176.2631

CAS No. 113513-61-4

3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-

Catalog No.:AG0008U3 MDL No.:

MF:C13H12N2O3S MW:276.3110

CAS No. 113513-63-6

3-Pyridinecarboxamide, 2-chloro-N-[(4-methylphenyl)sulfonyl]-

Catalog No.:AG0008U2 MDL No.:

MF:C13H11ClN2O3S MW:310.7560

CAS No. 113513-65-8

3-Pyridinecarboxamide, 2-chloro-N-[(2-methylphenyl)sulfonyl]-

Catalog No.:AG0008VD MDL No.:

MF:C13H11ClN2O3S MW:310.7560

CAS No. 113515-15-4

Acetamide, N-methyl-2-[(2,4,6-trinitrophenyl)amino]-

Catalog No.:AG0008VC MDL No.:

MF:C9H9N5O7 MW:299.1971

CAS No. 113515-22-3

2-Pyrimidinesulfonamide, N-(2-chloro-6-methylphenyl)-4,6-dimethyl-

Catalog No.:AG0008VB MDL No.:

MF:C13H14ClN3O2S MW:311.7872

CAS No. 113515-41-6

2-Pyrimidinesulfonyl fluoride, 4,6-dimethoxy-

Catalog No.:AG0008VA MDL No.:MFCD18816688

MF:C6H7FN2O4S MW:222.1942

CAS No. 113515-42-7

1,3,5-Triazine-2,4,6-triamine, N2,N2,N4,N4,N6,N6-hexakis(2-nitroethyl)-

Catalog No.:AG0008V9 MDL No.:

MF:C15H24N12O12 MW:564.4243

CAS No. 113515-60-9

Quinolinium, 1,1'-(1,2-ethanediyl)bis-, dichloride (9CI)

Catalog No.:AG0008V8 MDL No.:

MF:C20H18Cl2N2 MW:357.2763

CAS No. 113515-64-3

1,8-Naphthalenediamine, N1,N8-bis(phenylmethyl)-

Catalog No.:AG0008V7 MDL No.:

MF:C24H22N2 MW:338.4449

CAS No. 113515-65-4

1-Naphthalenediazonium, 2-hydroxy-3-sulfo-

Catalog No.:AG0008V6 MDL No.:

MF:C10H7N2O4S+ MW:251.2386

CAS No. 113515-72-3

3-Quinolinecarboxylic acid, 4-chloro-8-ethyl-, ethyl ester

Catalog No.:AG0008V5 MDL No.:

MF:C14H14ClNO2 MW:263.7195

CAS No. 113516-22-6

1H-Imidazole, 5-(2,3-dihydro-2-methyl-1-methylene-1H-inden-2-yl)-

Catalog No.:AG0008V4 MDL No.:

MF:C14H14N2 MW:210.2744

CAS No. 113516-50-0

Urea, N-[6-[[(octylamino)carbonyl]amino]hexyl]-N'-(2-phenylethyl)-

Catalog No.:AG0008V3 MDL No.:

MF:C24H42N4O2 MW:418.6159

CAS No. 113516-58-8

2,4-Hexadienedioic acid, 3-hydroxy-

Catalog No.:AG0008V2 MDL No.:

MF:C6H6O5 MW:158.1088

CAS No. 113516-59-9

Guanosine, 2'-deoxy-1-(2-hydroxyethyl)-

Catalog No.:AG0008V1 MDL No.:

MF:C12H17N5O5 MW:311.2939

CAS No. 113516-70-4

1-Propanesulfonic acid, 3-[[3-hydroxy-4-[2-(5-nitro-2-pyridinyl)diazenyl]phenyl]propylamino]-, sodium salt (1:1)

Catalog No.:AG0008V0 MDL No.:

MF:C17H20N5NaO6S MW:445.4254

CAS No. 113516-71-5

Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)-rel-

Catalog No.:AG0008UZ MDL No.:

MF:C9H10FN MW:151.1808

CAS No. 113516-72-6

Acetamide, N-[4-(2,6-dioxo-3-piperidinyl)phenyl]-

Catalog No.:AG0008UY MDL No.:

MF:C13H14N2O3 MW:246.2619

CAS No. 113516-75-9

Butanoic acid, 2-phenyl-1,3-dioxan-5-yl ester

Catalog No.:AG0008UX MDL No.:

MF:C14H18O4 MW:250.2903

CAS No. 113516-80-6

3H-Naphth[2,3-e]indole-2-carboxylic acid, 3-methyl-, ethyl ester

Catalog No.:AG0008UW MDL No.:

MF:C20H17NO2 MW:303.3545

CAS No. 113516-90-8

Benzeneacetic acid, 4-(5-formyl-2-furanyl)-

Catalog No.:AG0008UV MDL No.:

MF:C13H10O4 MW:230.2161

CAS No. 113518-22-2

3-Butenenitrile, 3-[(3-aminopropyl)amino]-

Catalog No.:AG0008UU MDL No.:

MF:C7H13N3 MW:139.1982

CAS No. 113518-45-9

Benzenesulfonamide, 4-methyl-N-(6-phenanthridinylmethyl)-

Catalog No.:AG0008UT MDL No.:

MF:C21H18N2O2S MW:362.4448

CAS No. 113518-46-0

Acetamide, N-phenyl-2-[[4-phenyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]-

Catalog No.:AG0008US MDL No.:

MF:C21H17N5OS MW:387.4576

CAS No. 113518-49-3

Acetamide, N-(4-methoxyphenyl)-2-[[4-phenyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]-

Catalog No.:AG0008UR MDL No.:

MF:C22H19N5O2S MW:417.4836

CAS No. 113518-51-7

Acetamide, N-(2-nitrophenyl)-2-[[4-phenyl-5-(4-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]-

Catalog No.:AG0008UQ MDL No.:

MF:C21H16N6O3S MW:432.4551

CAS No. 113518-74-4

Butanoic acid, 1-ethoxypropyl ester

Catalog No.:AG0008UP MDL No.:

MF:C9H18O3 MW:174.2374

CAS No. 113518-78-8

Benzoic acid, 4-(nonyloxy)-, 4-pentylphenyl ester

Catalog No.:AG0008W2 MDL No.:

MF:C27H38O3 MW:410.5888

CAS No. 113518-79-9

Benzoic acid, 4-(decyloxy)-, 4-pentylphenyl ester

Catalog No.:AG0008W1 MDL No.:

MF:C28H40O3 MW:424.6154

CAS No. 113518-91-5

1,8-Naphthyridin-2-amine, 3,6-dibromo-

Catalog No.:AG0008W0 MDL No.:

MF:C8H5Br2N3 MW:302.9534

CAS No. 113518-93-7

Hydrazinecarbothioamide, 2-formyl-N-phenyl-

Catalog No.:AG0008VZ MDL No.:

MF:C8H9N3OS MW:195.2416

CAS No. 113519-11-2

2H-Pyran-2-one, tetrahydro-6-phenyl-5-(phenylsulfonyl)-, cis- (9CI)

Catalog No.:AG0008VY MDL No.:

MF:C17H16O4S MW:316.3715

CAS No. 113519-12-3

2H-Pyran-2-one, tetrahydro-6-(2-phenylethenyl)-5-(phenylsulfonyl)-, cis- (9CI)

Catalog No.:AG0008VX MDL No.:

MF:C19H18O4S MW:342.4088

CAS No. 113519-26-9

2-Naphthaleneacetamide, N-methoxy-

Catalog No.:AG0008VW MDL No.:

MF:C13H13NO2 MW:215.2478

CAS No. 113519-61-2

2-Butenoic acid, 3-[(2,2-dicyano-1-phenylethenyl)amino]-, (Z)- (9CI)

Catalog No.:AG0008VV MDL No.:

MF:C14H11N3O2 MW:253.2560

CAS No. 113519-98-5

1H-Imidazole, 4-methyl-5-pentyl-

Catalog No.:AG0008VU MDL No.:

MF:C9H16N2 MW:152.2367

CAS No. 113520-01-7

4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 1,2,3,5,6,7-hexahydro-3-(2-propen-1-yl)-2-thioxo-

Catalog No.:AG0008VT MDL No.:MFCD00484384

MF:C12H12N2OS2 MW:264.3665

CAS No. 113520-12-0

Thiourea, N-(3-hydroxy-2-pyridinyl)-N'-methyl-

Catalog No.:AG0008VS MDL No.:

MF:C7H9N3OS MW:183.2309

CAS No. 113520-19-7

Oxazolo[4,5-b]pyridine, 2-(1-piperidinyl)-

Catalog No.:AG0008VR MDL No.:

MF:C11H13N3O MW:203.2404

CAS No. 113520-25-5

3-Thiophenethiol, tetrahydro-4-methyl-, 1,1-dioxide

Catalog No.:AG0008VQ MDL No.:

MF:C5H10O2S2 MW:166.2617

CAS No. 113520-28-8

1,3-Benzenediacetic acid, 1-ethyl ester

Catalog No.:AG0008VP MDL No.:

MF:C12H13O4- MW:221.2292

CAS No. 113520-36-8

1,4-Benzenediacetic acid, 4-ethyl ester

Catalog No.:AG0008VO MDL No.:

MF:C12H13O4- MW:221.2292

CAS No. 113520-43-7

Benzeneacetic acid, 3-(aminomethyl)-

Catalog No.:AG0008VN MDL No.:MFCD08275113

MF:C9H11NO2 MW:165.1891

CAS No. 113520-66-4

Propanoic acid, 2-methyl-3-(phenyltelluro)-, ethyl ester

Catalog No.:AG0008VM MDL No.:

MF:C12H16O2Te MW:319.8542

CAS No. 113520-72-2

1,2,4-Triazolidine-1-acetamide, N-acetyl-3,5-dioxo-4-phenyl-

Catalog No.:AG0008VL MDL No.:

MF:C12H12N4O4 MW:276.2481

CAS No. 113520-78-8

Propanedioic acid, 2-[2-(aminothioxomethyl)hydrazinylidene]-, 1,3-diethyl ester

Catalog No.:AG0008VK MDL No.:

MF:C8H13N3O4S MW:247.2715

CAS No. 113522-19-3

Benzenebutanenitrile, 2-methoxy-γ-oxo-

Catalog No.:AG0008VJ MDL No.:MFCD07700096

MF:C11H11NO2 MW:189.2105

CAS No. 113522-44-4

1,2-Ethanediamine, N1,N2-bis(phenylmethyl)-N1,N2-bis(trimethylsilyl)-

Catalog No.:AG0008VI MDL No.:

MF:C22H36N2Si2 MW:384.7056

CAS No. 113522-45-5

2-Butanol, 4-(triphenylmethoxy)-, (2R)-

Catalog No.:AG0008VH MDL No.:

MF:C23H24O2 MW:332.4355

CAS No. 113522-74-0

1-Butanol, 2-methylene-4-(phenylmethoxy)-

Catalog No.:AG0008VG MDL No.:

MF:C12H16O2 MW:192.2542

CAS No. 113523-39-0

2,4,7-Tetradecatriene, (E,E,Z)- (9CI)

Catalog No.:AG0008VF MDL No.:

MF:C14H24 MW:192.3404

CAS No. 113523-84-5

2-Butene-1,4-dione, 2-[(4-chlorophenyl)amino]-1,4-diphenyl-

Catalog No.:AG0008VE MDL No.:

MF:C22H16ClNO2 MW:361.8209

CAS No. 1135237-52-3

Imidazo[1,2-a]pyridine-3-carboxaldehyde, 6-bromo-, 2-methylhydrazone, [C(E)]-

Catalog No.:AG0008W8 MDL No.:

MF: MW:

CAS No. 113524-22-4

Bicyclo[4.2.0]octa-1,3,5,7-tetraene-7,8-diol, 3,4-dimethoxy-

Catalog No.:AG0008WR MDL No.:

MF:C10H10O4 MW:194.1840

CAS No. 113524-42-8

Cyclohexanecarboxylic acid, 4-(4-nitrophenyl)-, trans-

Catalog No.:AG0008WQ MDL No.:

MF:C13H15NO4 MW:249.2625

CAS No. 113524-84-8

Heptanoic acid, 3-chloro-6-methyl-2-oxo-, methyl ester

Catalog No.:AG0008WP MDL No.:

MF:C9H15ClO3 MW:206.6666

CAS No. 1135243-19-4

2,1,3-Benzothiadiazole-4-sulfonamide, N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-

Catalog No.:AG0008W7 MDL No.:

MF:C18H20N6O3S2 MW:432.5198

CAS No. 113525-06-7

3-Decene, 2-chloro-, (3E)-

Catalog No.:AG0008WO MDL No.:

MF:C10H19Cl MW:174.7109

CAS No. 113525-32-9

2-Dibenzothiophenemethanethiol

Catalog No.:AG0008WN MDL No.:

MF:C13H10S2 MW:230.3485

CAS No. 113525-69-2

4H-Quinolizine-1,3-dicarbonitrile, 6-methyl-4-oxo-

Catalog No.:AG0008WM MDL No.:

MF:C12H7N3O MW:209.2035

CAS No. 113525-73-8

1-Propene-1,1,3-tricarbonitrile, 3-(6-methyl-2(1H)-pyridinylidene)-, (E)- (9CI)

Catalog No.:AG0008WL MDL No.:

MF:C12H8N4 MW:208.2187

CAS No. 113525-77-2

3-Oxazolidinecarboxylic acid, 2-oxo-, 1,1-dimethylethyl ester

Catalog No.:AG0008WK MDL No.:

MF:C8H13NO4 MW:187.1931

CAS No. 113525-87-4

Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, methyl ester

Catalog No.:AG0008WJ MDL No.:MFCD18447448

MF:C9H17NO5 MW:219.2350

CAS No. 113525-94-3

Carbamic acid, N-(2-hydroxy-4-penten-1-yl)-, 1,1-dimethylethyl ester

Catalog No.:AG0008WI MDL No.:

MF:C10H19NO3 MW:201.2628

CAS No. 1135253-08-5

Benzenemethanol, 3-ethyl-4-fluoro-

Catalog No.:AG0008W6 MDL No.:MFCD17676554

MF:C9H11FO MW:154.1814

CAS No. 113526-00-4

Propanoic acid, 3-ethoxy-, 2-methoxy-1-methylethyl ester

Catalog No.:AG0008WH MDL No.:

MF:C9H18O4 MW:190.2368

CAS No. 113526-01-5

Propanoic acid, 3-ethoxy-, 2-ethylhexyl ester

Catalog No.:AG0008WG MDL No.:

MF:C13H26O3 MW:230.3437

CAS No. 113526-45-7

3(2H)-Isothiazolone, 5-benzoyl-2-[(2-methoxyphenyl)methyl]-

Catalog No.:AG0008WF MDL No.:

MF:C18H15NO3S MW:325.3816

CAS No. 113527-33-6

4-Isoquinolinol, 8-amino-1,2,3,4-tetrahydro-2-methyl-4-phenyl-

Catalog No.:AG0008WE MDL No.:

MF:C16H18N2O MW:254.3269

CAS No. 113527-38-1

Oxirane, 2-octatriacontyl-

Catalog No.:AG0008WD MDL No.:

MF:C40H80O MW:577.0626

CAS No. 113527-40-5

Propanedioic acid, 2-(2-naphthalenylmethyl)-2-[(tetrahydro-2-furanyl)methyl]-

Catalog No.:AG0008WC MDL No.:

MF:C19H20O5 MW:328.3591

CAS No. 113527-48-3

L-Valinamide, N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-tyrosyl- (9CI)

Catalog No.:AG0008WB MDL No.:

MF:C26H32N4O5S MW:512.6211

CAS No. 113528-07-7

Benzamide, 3,4,5-triethoxy-N-[(2-naphthalenylamino)thioxomethyl]-

Catalog No.:AG0008WA MDL No.:

MF:C24H26N2O4S MW:438.5392

CAS No. 113528-08-8

1,3,5-Triazine-2,4-diamine, N2-(2-ethoxyphenyl)-

Catalog No.:AG0008W9 MDL No.:

MF:C11H13N5O MW:231.2538

CAS No. 1135283-08-7

Pyrimidine, 5-bromo-2-ethynyl-

Catalog No.:AG0008W5 MDL No.:MFCD11840983

MF:C6H3BrN2 MW:183.0054

CAS No. 1135283-10-1

Benzene, 1-ethynyl-2-methoxy-4-nitro-

Catalog No.:AG0008W4 MDL No.:MFCD11840985

MF:C9H7NO3 MW:177.1568

CAS No. 1135283-23-6

Benzenepropanenitrile, β-oxo-4-(1-piperidinyl)-

Catalog No.:AG0008W3 MDL No.:MFCD12025857

MF:C14H16N2O MW:228.2896

CAS No. 1135283-33-8

4-Pyridinecarboxylic acid, 2,3-dichloro-5-(trifluoromethyl)-

Catalog No.:AG0008X0 MDL No.:MFCD12025872

MF:C7H2Cl2F3NO2 MW:259.9975

CAS No. 1135283-37-2

Imidazo[1,2-a]pyridine-2-acetic acid, 6-chloro-8-iodo-, methyl ester

Catalog No.:AG0008WZ MDL No.:MFCD11840999

MF:C10H8ClIN2O2 MW:350.5402

CAS No. 1135283-39-4

Imidazo[1,2-a]pyridine-2-carboxylic acid, 8-iodo-6-(trifluoromethyl)-, ethyl ester

Catalog No.:AG0008WY MDL No.:MFCD11841000

MF:C11H8F3IN2O2 MW:384.0931

CAS No. 1135283-53-2

1H-Pyrrolo[2,3-b]pyridine-3-carboxaldehyde, 5-(trifluoromethyl)-

Catalog No.:AG0008WX MDL No.:MFCD11841013

MF:C9H5F3N2O MW:214.1440

CAS No. 1135283-86-1

Benzenemethanol, 3-bromo-4-[(3,5-dimethylphenyl)methoxy]-

Catalog No.:AG0008WW MDL No.:MFCD11841061

MF:C16H17BrO2 MW:321.2090

CAS No. 1135288-77-5

Phenol, 4-(1-aminopropyl)-, hydrochloride (1:1)

Catalog No.:AG0008WV MDL No.:MFCD11226487

MF:C9H14ClNO MW:187.6666

CAS No. 113529-95-6

Benzo[b]thiophenecarbonitrile, 4,5,6,7-tetrahydro- (9CI)

Catalog No.:AG0008XG MDL No.:

MF:C9H9NS MW:163.2395

CAS No. 113530-01-1

Cyclopentanecarboxylic acid, methyl-, ethenyl ester (9CI)

Catalog No.:AG0008XF MDL No.:

MF:C9H14O2 MW:154.2063

CAS No. 113530-04-4

Butanedioic acid, pentylidene-, monoethyl ester (9CI)

Catalog No.:AG0008XE MDL No.:

MF:C11H17O4- MW:213.2503

CAS No. 113531-87-6

[1,1'-Bianthracene]-9,9',10,10'-tetrone, 5,6,7,8-tetrahydro-4,4',5,6,6',7,8-heptahydroxy-2,2'-dimethoxy-7,7'-dimethyl-, (1S,5S,6R,7S,8R)-

Catalog No.:AG0008XD MDL No.:

MF:C32H26O13 MW:618.5410

CAS No. 113531-94-5

Ethanone, 1-[(3S,4S)-tetrahydro-5-hydroxy-4-methyl-3-furanyl]-

Catalog No.:AG0008XC MDL No.:

MF:C7H12O3 MW:144.1684

CAS No. 1135318-65-8

Butanedioic acid, 2-hydroxy-, 1,4-diethyl ester, sodium salt (1:1)

Catalog No.:AG0008WU MDL No.:

MF:C8H14NaO5 MW:213.1835

CAS No. 1135324-00-3

1H-Pyrazole-4-carbonitrile, 5-amino-1-(4-aminophenyl)-

Catalog No.:AG0008WT MDL No.:MFCD10686726

MF:C10H9N5 MW:199.2120

CAS No. 113533-27-0

9H-Fluoren-9-ol, 3,6-dimethoxy-9-(2,4,6-trimethylphenyl)-

Catalog No.:AG0008XB MDL No.:

MF:C24H24O3 MW:360.4456

CAS No. 113533-65-6

1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[(methylamino)methyl]-1-pyrrolidinyl]-4-oxo-

Catalog No.:AG0008XA MDL No.:

MF:C18H21FN4O3 MW:360.3827

CAS No. 113534-02-4

1-Piperazinecarboxylic acid, 4-cyano-, 1,1-dimethylethyl ester

Catalog No.:AG0008X9 MDL No.:MFCD09029184

MF:C10H17N3O2 MW:211.2609

CAS No. 113534-13-7

2-Propanol, 1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, (2S)- (9CI)

Catalog No.:AG0008X8 MDL No.:MFCD09951939

MF:C9H22O2Si MW:190.3553

CAS No. 113534-14-8

2-Propanol, 1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, benzoate, (S)- (9CI)

Catalog No.:AG0008X7 MDL No.:

MF:C16H26O3Si MW:294.4613

CAS No. 113534-16-0

L-Asparagine, N-[bis(4-methoxyphenyl)methyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-

Catalog No.:AG0008X6 MDL No.:

MF:C34H32N2O7 MW:580.6271

CAS No. 113534-17-1

L-Glutamine, N-[bis(4-methoxyphenyl)methyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-

Catalog No.:AG0008X5 MDL No.:MFCD00065644

MF:C35H34N2O7 MW:594.6537

CAS No. 1135351-95-9

Benzenamine, 4-bromo-N-(1,1-dimethylethyl)-2-nitro-

Catalog No.:AG0008WS MDL No.:MFCD12756414

MF:C10H13BrN2O2 MW:273.1264

CAS No. 113537-11-4

1H-Indole-3-acetic acid, 4,5-dichloro-, methyl ester

Catalog No.:AG0008X4 MDL No.:

MF:C11H9Cl2NO2 MW:258.1007

CAS No. 113537-12-5

1H-Indole-3-acetic acid, 5,6-dichloro-, butyl ester

Catalog No.:AG0008X3 MDL No.:

MF:C14H15Cl2NO2 MW:300.1804

CAS No. 113537-13-6

1H-Indole-3-acetic acid, 5,6-dichloro-, methyl ester

Catalog No.:AG0008X2 MDL No.:

MF:C11H9Cl2NO2 MW:258.1007

CAS No. 113537-76-1

Propanedioic acid, 2-[2-(diethoxyphosphino)ethyl]-, 1,3-diethyl ester

Catalog No.:AG0008X1 MDL No.:

MF:C13H25O6P MW:308.3078

CAS No. 113540-55-9

Mercury, bromo(1-phenylethyl)-

Catalog No.:AG0008XV MDL No.:

MF:C8H9BrHg MW:385.6511

CAS No. 113540-68-4

Propanenitrile, 2-methyl-2-[4-(phenylamino)phenoxy]-

Catalog No.:AG0008XU MDL No.:

MF:C16H16N2O MW:252.3110

CAS No. 113540-75-3

1-Oxaspiro[4.4]nona-3,6-dien-2-one, 4,7-dimethyl-

Catalog No.:AG0008XT MDL No.:

MF:C10H12O2 MW:164.2011

CAS No. 113540-84-4

[2,2'-Binaphthalene]-1,4-dione, 7,7'-diacetyl-1',8,8'-trihydroxy-6,6'-dimethyl-

Catalog No.:AG0008XS MDL No.:

MF:C26H20O7 MW:444.4328

CAS No. 1135400-24-6

Benzenepropanoic acid, β-(2-pyridinylamino)-

Catalog No.:AG0008XJ MDL No.:MFCD21092072

MF:C14H14N2O2 MW:242.2732

CAS No. 113541-26-7

2,4-Hexadienoic acid, 6-(2-furanyl)-6-oxo-, ethyl ester, (2E,4E)-

Catalog No.:AG0008XR MDL No.:

MF:C12H12O4 MW:220.2213

CAS No. 113541-76-7

Cyclotridecane, 1-methoxy-2-methylene-

Catalog No.:AG0008XQ MDL No.:

MF:C15H28O MW:224.3822

CAS No. 113541-80-3

Cyclohexanecarboxylic acid, 2-oxo-1-(2-propen-1-yl)-, methyl ester

Catalog No.:AG0008XP MDL No.:

MF:C11H16O3 MW:196.2429

CAS No. 113541-81-4

Pyrrolidine, 1-[4-(phenylthio)-1-buten-1-yl]-

Catalog No.:AG0008XO MDL No.:

MF:C14H19NS MW:233.3724

CAS No. 113541-83-6

Heptanedioic acid, 4-formyl-4-[2-(phenylthio)ethyl]-, 1,7-dimethyl ester

Catalog No.:AG0008XN MDL No.:

MF:C18H24O5S MW:352.4452

CAS No. 113542-18-0

4-Pentenenitrile, 4-[(trimethylsilyl)methyl]-

Catalog No.:AG0008XM MDL No.:

MF:C9H17NSi MW:167.3235

CAS No. 113542-31-7

6-Heptenoic acid, 4-formyl-5-methyl-, methyl ester

Catalog No.:AG0008XL MDL No.:

MF:C10H16O3 MW:184.2322

CAS No. 1135424-15-5

1H-Indol-4-ol, 3-[2-(diethylamino)ethyl]-, 4-acetate

Catalog No.:AG0008XI MDL No.:MFCD04972027

MF:C16H22N2O2 MW:274.3581

CAS No. 113543-52-5

Benzeneacetic acid, α-azido-, phenylmethyl ester, (S)- (9CI)

Catalog No.:AG0008XK MDL No.:

MF:C15H13N3O2 MW:267.2826

© 2019 Angene International Limited. All rights Reserved.